Impact of advertisement and clinic populations in symptoms and perception of irritable bowel syndrome

Citation
Oy. Lee et al., Impact of advertisement and clinic populations in symptoms and perception of irritable bowel syndrome, ALIM PHARM, 13(12), 1999, pp. 1631-1638
Citations number
21
Categorie Soggetti
Pharmacology,"da verificare
Journal title
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN journal
02692813 → ACNP
Volume
13
Issue
12
Year of publication
1999
Pages
1631 - 1638
Database
ISI
SICI code
0269-2813(1999)13:12<1631:IOAACP>2.0.ZU;2-O
Abstract
Background: This study assessed the impact of recruitment on irritable bowe l syndrome clinical trials, by determining whether irritable bowel syndrome patients recruited from advertisement or a specialty clinic differ in clin ical and physiologic measures. Methods: We prospectively surveyed 657 irritable bowel syndrome patients wh o either: (i) were referred from a functional bowel disease clinic (52%); o r (ii) responded to advertisement for clinical trials (48%), using question naires about bowel and psychological symptoms, and quality of life. In a su bset of 42 irritable bowel syndrome patients (29 advertisement and 15 clini c patients), rectal discomfort thresholds were measured before and after re petitive sigmoid stimulation. Results: While the advertisement population more commonly consulted primary care physicians, the clinic population more commonly consulted gastroenter ologists. The clinic population reported more prevalent and severe abdomina l pain, and higher psychological symptom scores, while the advertisement po pulation had greater quality of life. In the visceral perception studies, b oth subgroups were hypersensitive to rectal distension. Conclusion: Compared to the clinic population, the advertisement population had less severe abdominal pain and psychological symptoms, better quality of life but similar visceral perception. The differences in clinical self-r eports may have consequences for enrolment of these different patient popul ations into clinical trials.